Countdown to VC Crossfire: Get Ready for Sparks to Fly on Thursday

We are chomping at the bit here at Xconomy Seattle about our next big event, circled in magic marker on my white board. This is the gathering we’re calling “VC Crossfire,” coming Thursday evening at Amazon’s new headquarters in Seattle’s South Lake Union neighborhood.

This event will bring together a fearsome foursome of some of the Northwest’s top technology entrepreneurs and financiers—Bob Nelsen of Arch Venture Partners; Tom Alberg of Madrona Venture Group; Andy Sack of TechStars Seattle and RevenueLoan; and Christopher Henney, the co-founder of Immunex, Icos, and Dendreon. They have agreed to subject themselves to the probing questioning of yours truly, and Xconomy national IT editor (and all-around cool dude) Greg Huang, who’s flying in from Boston for this big-time event.

Greg and I will get things started, and rove around the audience to seek out questions from you, so I’m going to advise you start thinking of what you’d like to say now to take advantage of this opportunity. We are, after all, talking about how innovative startups will get financed now that the venture capital industry as we have known it for decades is facing an existential crisis. You could say that the future of the Northwest will depend in part on how we all figure this out, so this is definitely not trivial stuff.

Once the panel has had their say during the crossfire portion of the evening, we’ll hear briefly from three entrepreneurs who each have one interesting financing approach to share with the audience. They are: Bill Harding of Bonanza, Tom Clement of Pathway Medical Technologies, and Kabir Shahani of Appature.

A few tickets are remaining, so if you’re a procrastinator, you are still in luck. You can get your tickets by clicking here. And be sure to stick around afterwards for beer, wine and light food, and some terrific networking. This event, after all, is really where the conversation starts, not where it ends.

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.